rafarma pharmaceuticals inc (RAFA) Key Developments
Rafarma Pharmaceuticals Inc. Appoints Mr. Bruno Horn as New President and Director
Jul 30 14
Rafarma Pharmaceuticals Inc. announced appointment of Mr. Bruno Horn as the new President and Director of the company, effective July 15, 2014. Mr. Horn is the founder of his own consultancy based in Switzerland, specializing in steel trading and the pharmaceutical industry.
Rafarma Pharmaceuticals Announces the Complete Restructuring of Existing EUR 90,000,000 Loan with VNeshconombank
Apr 2 14
Rafarma Pharmaceuticals Inc. announced the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank). Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.
Rafarma Pharmaceuticals, Inc. Enters New Distribution Agreement with Amber Pharma Distribution Group
Sep 10 13
Rafarma Pharmaceuticals, Inc. announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group.
New Dialysis Research and Development Center of Rafarma Pharmaceuticals, Inc. Devotes to Dialysis Research and Product Development
Aug 2 13
The success of Rafarma Pharmaceuticals, Inc. in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced. The new facility will be located near Rafarma's already-operating pharmaceutical plant in Terbuny in the Lipetsk region of Russia, a few hours south from Moscow. Rafarma and the dialysis facility plan to work in close cooperation in the development of dialysis-specific products. Terbuny is part of a special economic development region to promote economic growth and jobs in the area. For building and maintaining its facilities in Terbuny, as well as hiring local residents, Rafarma enjoys specific government incentives which enhance its bottom line.
Rafarma Pharmaceuticals, Inc. Announces Cooperative Research and Development Effort with Christian Albrecht University in Kiel, Germany
Jul 25 13
Rafarma Pharmaceuticals, Inc. announced a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects: The development of innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics. The goal is to create parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes; The development of products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics. The modifications are achieved by the creation of nano-crystals, which are formed through size reduction in the gas phase, as well as through synthetic crystallization.